A retrospective cohort study presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting suggests that early intervention with dupilumab in children with eosinophilic esophagitis (EoE) may lower the risk of developing asthma.
Researchers analyzed children who received dupilumab for EoE before the age at which the biologic is currently indicated for asthma treatment. Findings presented in Phoenix revealed that these children experienced approximately half the incidence of asthma 3.5 years later compared to a matched group of children who did not receive the biologic therapy.
Addressing the Treatment Gap
Dupilumab, a monoclonal antibody that inhibits interleukin-4 and interleukin-13 signaling, is the only FDA-approved biologic for EoE and is cleared for use in patients as young as 1 year old. Lead researcher Kayla J. Steinberger, MD, PhD, of West Virginia University, utilized the discrepancy between the drug's EoE and asthma approval ages to investigate whether early administration for esophageal inflammation could provide protective benefits against subsequent asthma development.
While the results indicate a significant association, the study authors noted that residual confounding by indication remains a possibility. Further research is required to confirm these findings and better understand the long-term clinical implications of early biologic intervention in pediatric patients.

